Replies to post #179637 on Biotech Values

[oc631]

you’re implicitly predicting that the nuke-free regimen of ABT-593 + ABT-530 and the nuke-free regimen of Alisporvir + EDP-239 will fail. I’ll make a note of that!

If your definition of failing is being inferior in certain genotypes, please make a note of it.